Cargando…
Response to: Once-nightly sodium oxybate (FT218) in the treatment of narcolepsy: a letter to the editor commenting on the recent publication by C. Kushida et al
Autores principales: | Kushida, Clete A, Roth, Thomas, Shapiro, Colin M, Roy, Asim, Rosenberg, Russell, Ajayi, Akinyemi O, Seiden, David, Gudeman, Jennifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265482/ https://www.ncbi.nlm.nih.gov/pubmed/35695179 http://dx.doi.org/10.1093/sleep/zsac042 |
Ejemplares similares
-
Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy
por: Kushida, Clete A, et al.
Publicado: (2021) -
Once-nightly sodium oxybate (FT218) in the treatment of narcolepsy: a letter
to the editor commenting on the recent publication by C. Kushida et al
por: Skobieranda, Franck, et al.
Publicado: (2022) -
Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial
por: Roth, Thomas, et al.
Publicado: (2022) -
Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial
por: Dauvilliers, Yves, et al.
Publicado: (2023) -
Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment
por: Morse, Anne Marie, et al.
Publicado: (2023)